↓ Skip to main content

Role and Therapeutic Potential of the Pro-Longevity Factor FOXO and Its Regulators in Neurodegenerative Disease

Overview of attention for article published in Frontiers in Pharmacology, January 2012
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
60 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Role and Therapeutic Potential of the Pro-Longevity Factor FOXO and Its Regulators in Neurodegenerative Disease
Published in
Frontiers in Pharmacology, January 2012
DOI 10.3389/fphar.2012.00015
Pubmed ID
Authors

Christian Neri

Abstract

Studies in simple model organisms have yielded crucial insights into the genetic and molecular aspects of longevity. FOXO, which is most notable for its association with longevity, and its upstream regulators such as sirtuins have received particular attention in translational research because these genes modulate cell survival in several models of neurodegenerative diseases. There is a large amount of knowledge on the pathways that regulate FOXO activity and genes that may be regulated by FOXO. However, for the same reason that the FOXO network is a complex stress response system, its therapeutic potential to develop disease-modifying strategies requires further examination. Although the FOXO network contains druggable genes such as sirtuins and AMPK, whether they should be activated or inhibited and whether protection against the early or late phases of neuronal cell decline might require opposite therapeutic strategies remains unclear. Additionally, the mode of action of small compound molecules believed to act on FOXO network targets was questioned. This review recapitulates essential facts and questions about the promises of FOXO and its interactors in neurodegenerative disease.

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 60 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
Netherlands 1 2%
Ireland 1 2%
Unknown 57 95%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 13 22%
Student > Doctoral Student 9 15%
Student > Bachelor 8 13%
Researcher 7 12%
Other 4 7%
Other 11 18%
Unknown 8 13%
Readers by discipline Count As %
Agricultural and Biological Sciences 21 35%
Medicine and Dentistry 14 23%
Biochemistry, Genetics and Molecular Biology 5 8%
Neuroscience 3 5%
Chemistry 2 3%
Other 5 8%
Unknown 10 17%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 September 2012.
All research outputs
#20,166,700
of 22,678,224 outputs
Outputs from Frontiers in Pharmacology
#9,875
of 15,847 outputs
Outputs of similar age
#221,187
of 244,101 outputs
Outputs of similar age from Frontiers in Pharmacology
#96
of 137 outputs
Altmetric has tracked 22,678,224 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 15,847 research outputs from this source. They receive a mean Attention Score of 4.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 244,101 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 137 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.